Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails
Author:
Publisher
Frontiers Media SA
Subject
Pharmacology (medical),Pharmacology
Reference59 articles.
1. Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma;Ahearne;Virchows Arch.,2014
2. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma;Ansell;N. Engl. J. Med.,2015
3. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial;Armand;J. Clin. Oncol.,2018
4. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure;Armand;J. Clin. Oncol.,2016
5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy;Frontiers in Immunology;2024-04-30
2. Advancements in Cancer Immunotherapy: Exploring Treatment Options;2024
3. An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer;Non-Coding RNA;2023-11-11
4. Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy;Molecular Cancer;2023-05-16
5. Hallmarks of Cancer Affected by the MIF Cytokine Family;Cancers;2023-01-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3